CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses

Bruce R Blazar, Patricia A Taylor, Randolph J. Noelle, Daniel A Vallera

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Abstract

A major goal of the transplant field is to tolerize donor T cells to prevent graft-versus-host disease (GVHD) (1). We describe an ex vivo approach in which the blockade of CD40 ligand (CD40L:CD154):CD40 interactions, a pathway required for optimal T cell expansion, induces donor CD4+ T cells to become tolerant to host alloantigens (2). High doses of tolerized cells did not cause GVHD lethality in vivo. T cells had intact responses to antigens not present during tolerization. Tolerance was long lived and not readily reversible in vivo. These data have significant implications for the use of tolerization approaches to prevent human GVHD.

Original languageEnglish (US)
Pages (from-to)473-482
Number of pages10
JournalJournal of Clinical Investigation
Volume102
Issue number3
DOIs
StatePublished - Aug 1 1998

Keywords

  • Allogeneic
  • Animal models
  • Immune tolerance
  • T lymphocytes
  • Transplantation
  • Transplantation immunology

Fingerprint

Dive into the research topics of 'CD4<sup>+</sup> T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses'. Together they form a unique fingerprint.

Cite this